Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linperlisib plus CHOP in newly diagnosed PTCL
NCT06548347Phase 3Not yet recruiting
- Sponsor
- Yingli Pharma
- Start
- Sep 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of linperlisib in peripheral T-cell lymphoma (PTCL) (3 arms), sponsored by Yingli Pharma. Primary endpoints: Overall response rate at 2 years and Progression-free survival at 2 years. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
linperlisib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06548347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548347.